Trial · NCT06719986
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 13 of 13
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Minute Ventilation 5 Minutes From Opioid Induced Nadir | 5 minutes after opioid antagonist administration | To assess the change in minute ventilation at 5 minutes of intramuscular nalmefene and intranasal naloxone reversal from the opioid induced nadir. |
| Secondary | Change in Minute Ventilation at 2.5, 5, 10, 15, 20, 30, and 90 Minutes From Opioid Induced Nadir | Baseline, 2.5, 5, 10, 15, 20, 30, and 90 minutes after opioid antagonist administration | To assess the time course of changes in minute ventilation of intramuscular nalmefene and intranasal naloxone reversal from the opioid induced nadir. |
| Secondary | Maximum Plasma Concentration (Cmax) | up to 24 hours post-dose | Maximum plasma concentration of nalmefene and naloxone. |
| Secondary | Area Under the Curve (AUC0-2.5) | 2.5 minutes post-dose | Area under the plasma concentration-time curve from time zero to 2.5 minutes |
| Secondary | Area Under the Curve (AUC0-5) | 5 minutes post-dose | Area under the plasma concentration-time curve from time zero to 5 minutes |
| Secondary | Area Under the Curve (AUC0-10) | 10 minutes post-dose | Area under the plasma concentration-time curve from time zero to 10 minutes |
| Secondary | Area Under the Curve (AUC0-15) | 15 minutes post-dose | Area under the plasma concentration-time curve from time zero to 15 minutes |
| Secondary | Area Under the Curve (AUC0-20) | 20 minutes post-dose | Area under the plasma concentration-time curve from time zero to 20 minutes |
| Secondary | Area Under the Curve (AUCt) | up to 24 hours post-dose | Area under the plasma concentration-time curve from time zero to the time of last measurable concentration. |
| Secondary | Area Under the Curve (AUCinf) | up to 24 hours post-dose | Area under the plasma concentration-time curve from time zero to infinity. |
| Secondary | Time to Maximum Plasma Concentration (Tmax) | up to 24 hours post-dose | Time to maximum plasma concentration of nalmefene and naloxone. |
| Secondary | Time to First Measurable Plasma Concentration (Tlag) | up to 24 hours post-dose | Time to first measurable plasma concentration of nalmefene and naloxone. |
| Secondary | Half-life (T1/2) | up to 24 hours post-dose | Half life of nalmefene and naloxone. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT06719986/registered